H.C. Wainwright Maintains Alkermes(ALKS.US) With Hold Rating, Maintains Target Price $37
Assessing Alkermes' ALKS-2680: A Hold Rating Amidst Potential and Prudence in Sleep Disorder Treatment
Analysts Conflicted on These Healthcare Names: Nurix Therapeutics (NRIX) and Alkermes (ALKS)
A Quick Look at Today's Ratings for Alkermes(ALKS.US), With a Forecast Between $32 to $50
Alkermes Price Target Maintained With a $48.00/Share by Cantor Fitzgerald
Cantor Fitzgerald Reiterates Overweight on Alkermes, Maintains $48 Price Target
Alkermes Analyst Ratings
A Quick Look at Today's Ratings for Alkermes(ALKS.US), With a Forecast Between $35 to $50
Mizuho Securities Initiates Alkermes(ALKS.US) With Buy Rating
Analysts Offer Insights on Healthcare Companies: Establishment Labs Holdings (ESTA), Alkermes (ALKS) and Axsome Therapeutics (AXSM)
Alkermes (ALKS) Gets a Hold From Leerink Partners
Piper Sandler Maintains Alkermes(ALKS.US) With Buy Rating, Cuts Target Price to $38
Piper Sandler Sticks to Its Buy Rating for Alkermes (ALKS)
Jefferies Maintains Alkermes(ALKS.US) With Buy Rating, Maintains Target Price $50
Alkermes Analyst Ratings
Cantor Fitzgerald Reiterates Overweight on Alkermes, Maintains $48 Price Target
Maintaining Hold on Alkermes: Weighing Solid Performance Against Seasonal Slowdown and Pipeline Uncertainties
A Quick Look at Today's Ratings for Alkermes(ALKS.US), With a Forecast Between $32 to $38
Alkermes Price Target Raised to $37.00/Share From $35.00 by HC Wainwright & Co.
HC Wainwright & Co. Maintains Neutral on Alkermes, Raises Price Target to $37